The Chicago Department of Public Health (CDPH) is a government department of the City of Chicago. The purpose of the Chicago Department of Public Health (CDPH) is too create a thriving and healthy community within the city of Chicago, Illinois by providing guidance, services and strategies. This includes promoting values of diversity, excellence, informed decision making, and teamwork within all residents and smaller communities within the city.
Women of transgender experience and transfeminine people (WTE/TFP) are disproportionately impacted by HIV. Between July 2023 and May 2024, a total of 2059 eligible WTE/TFP across nine project areas participated in the National HIV Behavioral Surveillance (NHBS-Trans) project. Among the 1993 participants with valid HIV test results, 35.7
Medetomidine, an alpha-2 adrenergic agonist, emerged as a U.S. drug adulterant in 2022. In May 2024, the Chicago Department of Public Health identified a cluster of opioid overdoses with unusual clinical features linked to medetomidine. We performed a retrospective chart review of patients presenting to three Chicago emergency departments with suspected opioid-involved overdoses during May 11–17, 2024. We classified cases as confirmed, probable, or suspected based on independent clinical criteria and laboratory screening results. We performed descriptive statistics and exploratory logistic regression to assess the association between case status and hospital outcomes. Out of 181 patients presenting with suspected opioid-involved overdoses during the one-week window, 15 patients identified during the initial phase of the outbreak underwent supplemental testing, yielding 12 laboratory-confirmed cases of medetomidine exposure. In patients with confirmed medetomidine exposure (n = 12), all exhibited persistent altered mental status despite naloxone administration and demonstrated marked hypertension at presentation. Bradycardia was present in 9 patients (75
To ascertain whether former small for gestational age (weight-for-gestational age < 10th percentile, SGA), compared to non-SGA, US-born women have greater SGA rates in their grandchildren. A multi-step strategy utilizing mother’s date of birth and full name was used to link the vital records of Chicago-born infants (born 2005–2017) to the Illinois transgenerational birth-file of their mothers (born 1989–1991) and maternal grandmothers (born 1956–1976). These matches accounted for differing naming practices, misspellings, and typographical errors. Our population was used to define generation-one women’s SGA based on sex. A population-based reference was used to define generation-three infant’s SGA based on sex average birthweight. Stratified and multivariable log binomial regression analyses were performed on singleton births. The Population Attributable Risk (PAR) percentages were calculated: PE|D * [(adjRR-1)/adjRR] were calculated. Former SGA women (n = 1510) had a greater percentage of SGA births in their grandchildren than former non-SGA women (n = 9466): 23.3
Importance Fibromyalgia is characterized by chronic widespread pain that is often exacerbated by movement that interferes with daily activities. Development of effective treatments for movement-evoked pain is essential for improving function for individuals with fibromyalgia. Objective To evaluate whether the addition of transcutaneous electrical nerve stimulation (TENS) to outpatient physical therapy improves fibromyalgia-associated movement-evoked pain. Design, Setting, and Participants The Fibromyalgia TENS in Physical Therapy (FM-TIPS) study was a cluster-randomized clinical trial of participants with fibromyalgia at 28 outpatient PT clinics from 6 health care systems. Between February 1, 2021, and September 31, 2024, 958 participants were screened, 459 participants enrolled, and 384 completed baseline data collection, with final data collected in March 2025. Intervention Clinics were randomized to PT plus TENS (PT-TENS) and PT-only groups. Data were captured on days 1, 30, 60 (primary end point, randomized phase), 90, and 180. Participants in the PT-only group received TENS after day 60 (extension phase). TENS was applied to the upper and lower back with instructions to use 2 hours daily with parameters of modulating frequency of 2 to 125 Hz for 100 to 180 microseconds at a strong but comfortable intensity. Main Outcomes and Measures The primary outcome was a change in movement-evoked pain (scale of 0-10, with 0 indicating no pain and 10 indicating worst pain imaginable) from baseline to day 60 rated during a 5-times sit-and-stand task using a linear mixed-effects model. In addition, patient-reported improvement based on the Patient Global Impression of Change score and patient-reported adverse events were assessed. Results A total of 384 FM-TIPS participants (mean [SD] age, 53 [15] years; 351 [91%] female) completed baseline data collection (modified intention-to-treat), with 191 individuals in PT-TENS group and 193 in PT-only group. Movement-evoked pain at day 60 during TENS treatment was significantly lower in the PT-TENS group compared with the PT-only group (group mean difference, −1.2; 95 CI, −1.6 to −0.7; d = 0.46). A dose-response effect for TENS was observed, with more participants in the PT-TENS group reporting improvement on the Patient Global Impression of Change (120 [72%] vs 86 [51%], P = .001) and a 30% or greater reduction in movement-evoked pain in responder analysis (66 of 161 [41%] vs 22 of 169 [13%]; P < .001). At day 180, 217 respondents (81%) found TENS helpful and 147 (55%) used TENS daily. There were no serious adverse events, and 109 of 358 (30%) experienced minor adverse events during the entire 6 months of the study. Conclusions and Relevance In this cluster randomized clinical trial of TENS in fibromyalgia, TENS meaningfully reduced movement-evoked pain and remained effective for 6 months. This study’s results suggest that TENS is a safe, inexpensive, and readily available treatment for fibromyalgia. Trial Registration ClinicalTrials.gov Identifier: NCT04683042
